|
Management of insomnia disorder |
Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, Koffel E, Khawaja IS, Ouellette J, Butler M, Kane RL, Wilt TJ |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, Koffel E, Khawaja IS, Ouellette J, Butler M, Kane RL, Wilt TJ. Management of insomnia disorder. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 159. 2015 Authors' objectives To assess the efficacy, comparative effectiveness, and harms of treatments for insomnia disorder in the general adult population and older adults. Authors' conclusions CBT-I or medical therapy with eszopiclone, zolpidem, and suvorexant improve global and sleep outcomes for insomnia disorder. Clinical significance, applicability, comparative effectiveness, and long-term efficacy, especially among older adults, are less well known. Effect sizes vary, and a large placebo response is sometimes observed. Observational studies suggest an association of hypnotics with infrequent but serious harms. FDA labels provide specific warnings and precautions for drugs approved for insomnia. Indexing Status Subject indexing assigned by CRD MeSH Adult; Azepines; Humans; Hypnotics and Sedatives; Pyridines; Sleep Initiation and Maintenance Disorders Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov AccessionNumber 32016000034 Date abstract record published 06/01/2016 |
|
|
|